Jianfeng Chen

5.8k citations
123 papers · 3.7k indexed · 2 hit papers · h-index 32

Impact in

  • Immunology top 2%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction
    • Immune cells in cancer
  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research

Papers in

    • Immune Cell Function and Interaction 8
    • Immunotherapy and Immune Responses 8
    • Complement system in diseases 7

Jianfeng Chen

118 papers receiving 3.7k citations

Hit Papers

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer 2017 · 455 citations
4552016202620192022250500750

Peers

Jianfeng Chen
Comparison fields: 5 of 131
  • Immunology 1.4k
  • Oncology 1.6k
  • Cancer Research 651
  • Molecular Biology 1.5k
  • Nephrology 92
Replace Yanhong Gu with:
Yanhong Gu China
Arshad Rahman United States
Saverio Candido Italy
Shabnam Shalapour United States
F. Javier Oliver Spain
Huakan Zhao China
Michitaka Ozaki Japan
Emeric Limagne France
John J. Arcaroli United States
Jianfeng Chen relative to Yanhong Gu China Yanhong Gu's profile →
Citations per field
00.5×1.7×
Yanhong Gu · 1×
Citations per year

Countries citing papers authored by Jianfeng Chen

Since Specialization
Citations

This map shows the geographic impact of Jianfeng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianfeng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianfeng Chen more than expected).

Fields of papers citing papers by Jianfeng Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianfeng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianfeng Chen. The network helps show where Jianfeng Chen may publish in the future.

Co-authors

The 25 scholars most cited alongside Jianfeng Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jianfeng Chen Line = papers co-authored together Jianfeng Chen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20243
4 202419
5 202417
6 20241
7 20234
8 202315
9 20233
10 20227
11 20229
12 20214
13 202045
14 201935
15
Inhibition of human glioblastoma cell invasion involves PION@E6 mediated autophagy process
20191
16
Dihydrotanshinone I inhibits the growth of osteosarcoma through the Wnt/β-catenin signaling pathway
20191
17 201546
18 201527
19 201244
20 200736

About Jianfeng Chen

Jianfeng Chen is a scholar working on Immunology, Cancer Research, Complementary and alternative medicine, Molecular Biology and Oncology, having authored 123 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Immune Cell Function and Interaction (8 papers), Immunotherapy and Immune Responses (8 papers), Autophagy in Disease and Therapy (7 papers), Complement system in diseases (7 papers), RNA modifications and cancer (6 papers), Estrogen and related hormone effects (6 papers) and Natural product bioactivities and synthesis (6 papers). The work is most often cited by research in Immunology (1.4k citations), Oncology (1.6k citations), Cancer Research (651 citations), Molecular Biology (1.5k citations) and Nephrology (92 citations). Jianfeng Chen has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Padmanee Sharma, Jianjun Gao, James P. Allison, Lewis Z. Shi, Hao Zhao, Jennifer A. Wargo, Liangwen Xiong, Tenghui Chen, Qiuming He and Patrick Hwu. Their work appears in journals such as Cell Death and Disease, Molecules, Journal of Biological Chemistry, International Immunopharmacology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026